2496-PUB: Effect of Body Mass Index on HbA1c, Blood Pressure, and Cholesterol (ABC) Control in Patients with Type 2 Diabetes from Tibet in China

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 2496-PUB
Author(s):  
ZHANG CHENGHUI ◽  
LI MINGXIA ◽  
WANG SUYUAN ◽  
WU YUNHONG
Keyword(s):  
Blood Pressure ◽  
Type 2 Diabetes ◽  
Body Mass Index ◽  
Body Mass

scholarly journals The effects of metformin plus sulfonylurea therapy on clinical features of the metabolic syndrome

2010 ◽  
Vol 63 (9-10) ◽  
pp. 611-615 ◽  
Author(s):  
Branka Koprivica ◽  
Teodora Beljic-Zivkovic ◽  
Tatjana Ille
Keyword(s):  
Insulin Resistance ◽  
Blood Pressure ◽  
Type 2 Diabetes ◽  
Metabolic Syndrome ◽  
Body Mass Index ◽  
Waist Circumference ◽  
Glycemic Control ◽  
Body Mass ◽  
Combined Therapy

Introduction. Insulin resistance is a well-known leading factor in the development of metabolic syndrome. The aim of this study was to evaluate metabolic effects of metformin added to sulfonylurea in unsuccessfully treated type 2 diabetic patients with metabolic syndrome. Material and methods. A group of thirty subjects, with type 2 diabetes, secondary sulfonylurea failure and metabolic syndrome were administered the combined therapy of sulfonylurea plus metformin for six months. Metformin 2000 mg/d was added to previously used sulfonylurea agent in maximum daily dose. Antihypertensive and hypolipemic therapy was not changed. The following parameters were assessed at the beginning and after six months of therapy: glycemic control, body mass index, waist circumference, blood pressure, triglycerides, total cholesterol and its fractions, homeostatic models for evaluation of insulin resistance and secretion (HOMA R, HOMA B) and C- peptide. Results. Glycemic control was significantly improved after six months of the combined therapy: (fasting 7.89 vs. 10.61 mmol/l. p<0.01; postprandial 11.12 vs. 12.61 mmol/l. p<0.01, p<0.01; glycosylated hemoglobin 6.81 vs. 8.83%. p<0.01). the body mass index and waist circumference were significantly lower (26.7 vs. 27.8 kg/m2, p<0.01 and 99.7 vs. 101.4 cm for men, p<0.01; 87.2 vs. 88.5 for women, p<0.01). Fasting plasma triglycerides decreased from 3.37 to 2.45 mmol/l (p<0.001) and HOMA R from 7.04 to 5.23 (p<0.001). No treatment effects were observed on blood pressure, cholesterol, and residual insulin secretion. Conclusion. Administration of metformin in type 2 diabetes with metabolic syndrome decreased cardiovascular risk factors by reducing glycemia, triglycerides, BMI, central obesity and insulin resistance.

Quality of Life, Glycemic Control, Safety and Tolerability Associated with Liraglutide or Insulin Initiation in Patients with Type 2 Diabetes in Germany: Results from the Prospective, Non-interventional LIBERTY Study

2018 ◽  
Vol 128 (03) ◽  
pp. 170-181 ◽  
Author(s):  
Rainer Lundershausen ◽  
Sabrina Müller ◽  
Mahmoud Hashim ◽  
Joachim Kienhöfer ◽  
Stefan Kipper ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Blood Pressure ◽  
Type 2 Diabetes ◽  
Body Mass Index ◽  
Glycemic Control ◽  
Body Mass ◽  
Severe Hypoglycemia ◽  
Insulin Initiation

Abstract Purpose To assess quality of life, glycemic control, and safety/tolerability associated with liraglutide versus insulin initiation in patients with type 2 diabetes in Germany. Methods Liraglutide/insulin-naïve adults with type 2 diabetes and inadequate glycemic control despite using oral antidiabetic medication were assigned to liraglutide (≤1.8 mg daily; n=878) or any insulin (n=382) according to the treating physician’s decision and followed for 52 weeks. The primary objective was to evaluate Audit of Diabetes-Dependent Quality of Life (ADDQoL) scores. Results At baseline, the liraglutide group was younger and had shorter type 2 diabetes duration, lower glycated hemoglobin (HbA1c), higher body mass index, and a lower prevalence of certain diabetes-related complications than the insulin group (all p<0.05). ADDQoL average weighted impact scores improved numerically in both groups from baseline to 52 weeks (mean difference [95% confidence interval], liraglutide vs. insulin: 0.159 [−0.023;0.340]; not significant). Changes in general wellbeing and five ADDQoL domains significantly favored liraglutide (remaining 14 domains, not significant). HbA1c reductions were greater with insulin than liraglutide (−2.0% vs. −1.2%; p<0.01); however, mean HbA1c after 52 weeks was 7.2% in both groups. Compared with insulin, liraglutide significantly decreased body mass index (−1.54 kg/m2 vs. +0.27 kg/m2; p<0.001), systolic blood pressure (−5.03 mmHg vs. −1.03 mmHg; p<0.01) and non-severe hypoglycemia (0.85% vs. 4.55% at 52 weeks; p<0.01). Adverse drug reactions were reported for<3% of patients in both groups. Conclusions Liraglutide improved certain ADDQoL components and reduced body mass index, systolic blood pressure, and non-severe hypoglycemia versus insulin. Both treatments improved glycemic control.

scholarly journals Effectiveness of PRECEDE model for health education on changes and level of control of HbA1c, blood pressure, lipids, and body mass index in patients with type 2 diabetes mellitus

2011 ◽  
Vol 11 (1) ◽  
Author(s):  
Miguel A Salinero-Fort ◽  
Enrique Carrillo-de Santa Pau ◽  
Francisco J Arrieta-Blanco ◽  
Juan C Abanades-Herranz ◽  
Carmen Martín-Madrazo ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Blood Pressure ◽  
Type 2 Diabetes ◽  
Body Mass Index ◽  
Type 2 Diabetes Mellitus ◽  
Health Education ◽  
Body Mass

scholarly journals THE BODY MASS INDEX INFLUENCES THE ACHIEVEMENT RATIO OF TARGET BLOOD PRESSURE BY SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS IN JAPANESE TYPE 2 DIABETES PATIENTS WITH CKD

2021 ◽  
Vol 39 (Supplement 1) ◽  
pp. e211
Author(s):  
Kazuo Kobayashi ◽  
Kouichi Tamura ◽  
Masao Toyoda ◽  
Hiroyuki Sakai ◽  
Takayuki Furuki ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Type 2 Diabetes ◽  
Body Mass Index ◽  
Body Mass ◽  
The Body ◽  
Target Blood Pressure ◽  
Sodium Glucose Cotransporter ◽  
Diabetes Patients

scholarly journals Investigating high blood pressure, type-2 diabetes, dislipidemia, and body mass index to determine the health status of people over 30 years

2020 ◽  
Vol 9 (1) ◽  
pp. 333
Author(s):  
Fakhreddin Chaboksavar ◽  
Abdolhamid Zokaei ◽  
Arash Ziapour ◽  
MasoumehErfani khanghahi ◽  
JavadYoosefi Lebni ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Type 2 Diabetes ◽  
Body Mass Index ◽  
Health Status ◽  
Body Mass ◽  
High Blood Pressure

Abstract P106: Blood Pressure Regulation After Lisinopril Therapy in Persons With Diabetes

Hypertension ◽  
2017 ◽  
Vol 70 (suppl_1) ◽  
Author(s):  
Vesna Stojanov ◽  
Katarina Paunovic ◽  
Branko Jakovljevic ◽  
Zorica Milenkovic Vicentijevic
Keyword(s):  
Blood Pressure ◽  
Type 2 Diabetes ◽  
Body Mass Index ◽  
Body Mass ◽  
Antihypertensive Therapy ◽  
Prediction Models ◽  
Smoking Habits ◽  
Initiation Of Therapy ◽  
Regulation Of Blood Pressure

Objectives: The aim of this study was to assess the regulation of blood pressure after three months of antihypertensive therapy in persons with type 2 diabetes mellitus. Design and Methods: The study sample consisted of 398 persons with arterial hypertension and type 2 diabetes, aged 63.9±9.6 years. Hypertension was treated with 10 mg lisinopril (98 patients), 20 mg lisinopril (140 patients), or with fixed combination of 20 mg lisinopril and 12.5 mg hydrochlorothiazide (160 patients). Blood pressure (BP) was measured by an oscillometric device at the beginning of the study, one month later, and after three months of therapy. A ‘well-regulated’ blood pressure was defined as systolic BP less than 140 mmHg, and/or diastolic BP less than 90 mmHg one month and three months after the initiation of therapy. Logistic regression was used to predict good regulation of SBP and DBP after three months of therapy in relation to age, gender, smoking habits, body mass index, and regulation of blood pressure one month after the beginning of therapy. Results: At the beginning of the study, the average SBP was 159.4±12.7 mmHg, average DBP was 96.3±8.5 mmHg. After one month, average SBP was 140.5±18.6 mmHg, average DBP was 87.8±8.1 mmHg. At that stage, SPB was well-regulated in 127 persons (31.9% of the sample), whereas DBP was well-regulated in 189 persons (47.5% of the sample). After three months of therapy, average SBP was 132.4±9.0 mmHg, and average DBP was 81.6±6.0 mmHg. At that stage, SPB was well-regulated in 286 persons (71.9% of the sample), whereas DBP was well-regulated in 339 persons (85.2% of the sample). The only significant predictor for the good regulation of SBP after three months of therapy was good regulation of SBP one month after the beginning of therapy (Odds Ratio=2.44; 95% Confidence Interval =1.44-4.13). The only significant predictor for the good regulation of DBP after three months was good regulation of DBP one month after the beginning of therapy (OR=8.08; 95% CI =3.71-17.63). These prediction models were independent of age, gender, body mass index, smoking habits, and lisinopril treatment. Conclusion: The regulation of BP after three months of antihypertensive therapy with lisinopril depends on the good regulation of BP one month after the initiation of therapy.

Evaluation of vibration sensitivity violation as early diagnosis of diabetic distal polyneuropathy in patients with type 2 diabetes

2016 ◽  
Vol 62 (5) ◽  
pp. 16-17
Author(s):  
Alexandra Sosedkova ◽  
Yulia Dydyshka
Keyword(s):  
Blood Pressure ◽  
Type 2 Diabetes ◽  
Body Mass Index ◽  
Early Diagnosis ◽  
Body Mass ◽  
Clinical Symptoms ◽  
Vibration Sensitivity ◽  
New Device ◽  
Previous Diagnosis

Distal sensorimotor polyneuropathy (DSPN) is a severe complication and the most common form of peripheral neuropathies in patients with type 2 diabetes (T2D). Nowadays, interest in the DSPN has increased significantly due to the increase of incidence of T2D, as well as the severity of its clinical manifestations.This study aimed to assess the prevalence of DSPN in patients with T2D using Vibratip device as an alternative test for early diagnosis of vibration perception disorders.Design and methods. This study was a cross sectional observational design. Height, weight, body mass index (BMI), systolic and diastolic blood pressure measured according to standard protocol. The information about T2D duration and treatment, diabetic complications, concomitant diseases and its treatment, data about laboratory parameters (level of HbA1c during the last six months, total cholesterol and triglycerides) collected from local database. All participants examined with Vibratip on both feet. Vibratip is new device using standardized vibration for DSPN detection. Vibratip is applied to the patients feet, testing two sites on both feet (1st metatarsal head on the plantar surface and hallux pump) - once whilst non-vibrating and once whilst vibrating and the patients (with their eyes closed) is asked to indicate when they feel the vibration.Results. 2757 women and 1546 men aged 22-89 years selected from the six regions of the Republic of Belarus and Minsk-city. Among the 4303 subjects 7.78% (n=335) took place in this study aged less than 45 years (young patients), 65.4 % (n=2814) aged 45-65 years and 26.49 % (n=1140) aged more than 65 years old. Average age was 59 ±10.4; average body mass index (BMI) – 32.2±5.6 kg/m2. Participants with normal body mass index composed 9.02% (n=388), participants with superfluous body mass and obesity – 91% (n=3915). 710 (16.5%) participants were smoking, 2649 (61 %) suffered from high blood pressure. The most participants 1428 (33%) were treated by statins compared with fibrates 131 (3%). In patients with clinical symptoms of DSPN more often was pain (in 775 cases - 18.0%), burning (in 775 cases - 16.4%), numbness (in 1144 cases - 26.6%), feeling of pins and needles (in 921cases - 21.4%) and feeling of electric shock (in 235 cases - 5.5%). In patients with vibration sensitivity disorders were subjects with previous diagnosis of DSPN 1813 (42.13%) and subjects without previous diagnosis of DSPN 850 (19.75%). Amount subjects with asymptomatic vibration sensitivity disorder without clinical symptoms DSPN was 1640 (38.12%).Conclusions. In 20% of patients T2D with impaired vibration sensitivity, established with the device Vibratip, defined pre-clinical stage of DSPN. Given the ease of use of the device Vibratip advisable its use as a screening method for early diagnosis of DSPN in clinical practice. 

Sign in / Sign up

Export Citation Format

Share Document